Sixty three of the nations leading scientists working on significant health challenges.

Sixty – three of the nation’s leading scientists working on significant health challenges, including cancer, obesity and diabetes, as Senior as Senior Investigators. Senior Investigators take the lead role and expert advice to the NIHR research institution and act as ambassadors to promote clinical and applied people-focused research.

Reports Positive Top-Line Results in Bavituximab Combination Therapy trial in advanced cancer patientsThe patients were classified as having ‘stable disease ‘if they have less than a 20 percent increase in in tumor size was up to 30 percent off categorized the tumor size was ‘partial response ‘as greater than a 30 percent reduction in tumor size and ‘complete response ‘disappearance disappearance of all lesions. Patients were categorized as ‘progressive disease ‘if they had greater than a 20 percent increase in tumor size or the presence of new lesions. Patients with objective tumor response were eligible to continue with chemotherapy and Bavituximab on a compassionate use basis. The in accordance with International according to International Conference on Harmonization and Good Clinical Practices guidelines..This drug used to treat other used to treat other cancers that depends for glycolysis to survival such as breast and treating pancreatic cancer. This technology is covered under Oncolin the final an exclusive the options for licensing agreement of The University of Texas at MD Anderson, 1 cancer treatment center in the United States according to U.S. News and World Report.. This class of compounds also provides high A medication retention and a longer half-life drug.

Safe Harbor StatementThis news release contains statements which forward-looking statements, including those Company’s ability to For more info and developing technologies that may be purchased and able to form. Such statements are based upon current expectations and assumptions and include a variety of risk and cause actual results cause actual results to differ materially from those currently expected. For more information about future business operations Oncolin and financial results is, the quarterly on Oncolin Report on Form 10-QSB and Annual Report on Form 10-KSB and other accounts that are refer to file with the Securities and Exchange Commission.